



REVIEW ARTICLE

Cardiotoxicity associated with cancer therapy: Pathophysiology and prevention[☆]

Rui Adão^a, Gilles de Keulenaer^b, Adelino Leite-Moreira^a, Carmen Brás-Silva^{a,*}

^a Departamento de Fisiologia e Cirurgia Cardiorádica, Faculdade de Medicina, Universidade do Porto, Porto, Portugal

^b Laboratory of Physiology, University of Antwerp, Antwerp, Belgium

Received 21 September 2012; accepted 1 November 2012

Available online 10 June 2013

KEYWORDS

Cardiotoxicity;
Cardiomyopathy;
Chemotherapy;
Anthracyclines;
Radiotherapy;
Trastuzumab;
HER2

PALAVRAS-CHAVE

Efeitos cardiotoxícos;
Cardiomiopatia;
Quimioterapia;
Antraciclina;
Radioterapia;
Trastuzumab;
erbB

Abstract Cardiotoxicity is one of the most significant adverse effects of cancer treatment, and is responsible for considerable morbidity and mortality. Among the effects of chemotherapeutic agents on the cardiovascular system, the most frequent and serious is heart failure with ventricular systolic dysfunction. Other toxic effects include hypertension, thromboembolic disease, pericardial disease, arrhythmias and myocardial ischemia. For several decades, cancer therapy-induced cardiomyopathy was almost exclusively associated with the use of cumulative doses of anthracyclines, which cause permanent damage at the cellular level. However, new therapeutic agents, such as the monoclonal antibody trastuzumab, induce transient reversible myocyte dysfunction which is unrelated to the dose used. Early identification of potential cardiovascular injury, accurate diagnosis of cardiotoxic events and implementation of appropriate monitoring plans are essential in patients with cancer. Close cooperation between cardiologists and oncologists is thus crucial, in order to balance the risks and benefits of cardiotoxic anti-cancer therapy. In this article we review the various responses to cardiotoxic cancer treatments and their relationship with the main antineoplastic drugs used in clinical practice. In addition, we discuss the main guidelines on detection and monitoring of cardiotoxicity in patients with cancer.

© 2012 Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L. All rights reserved.

Cardiotoxicidade associada à terapêutica oncológica: mecanismos fisiopatológicos e estratégias de prevenção

Resumo A cardiotoxicidade é um dos efeitos adversos mais significativos do tratamento oncológico, responsável por uma considerável morbimortalidade. Entre os eventos lesivos dos agentes/fármacos quimioterápicos no sistema cardiovascular, destaca-se, pela sua maior frequência e gravidade, a ocorrência de insuficiência cardíaca com disfunção ventricular sistólica. Outros efeitos tóxicos cardiovasculares incluem hipertensão arterial, doença tromboembólica,

[☆] Please cite this article as: Adão R, et al. Cardiotoxicidade associada à terapêutica oncológica: mecanismos fisiopatológicos e estratégias de prevenção. Rev Port Cardiol. 2013. <http://dx.doi.org/10.1016/j.repc.2012.11.002>.

* Corresponding author.

E-mail address: carmensb@med.up.pt (C. Brás-Silva).

doenças pericárdicas, arritmias e isquemia miocárdica. Durante várias décadas, a cardiomiopatia induzida por terapêutica oncológica era quase exclusivamente associada ao uso de doses cumulativas de antraciclinas, que promovem lesões permanentes a nível celular. No entanto, o uso de novos agentes terapêuticos, como o anticorpo monoclonal *trastuzumab*, induz uma disfunção transitória reversível dos miócitos sem que haja relação com a dose utilizada. Atualmente, é essencial para os doentes com cancro a identificação precoce da lesão cardiovascular, o diagnóstico preciso de eventos cardiotóxicos e a implementação de planos de monitorização adequados. Neste contexto, é fulcral na prática clínica uma cooperação estreita entre cardiologistas e oncologistas, de forma a equilibrar os riscos cardiotóxicos com os benefícios da terapia antineoplásica em doentes oncológicos. Neste artigo revimos as diversas respostas cardiotóxicas ao uso de tratamentos oncológicos e a sua relação com os principais fármacos antineoplásicos usados na prática clínica. Além disso, serão abordadas as principais linhas de orientação no que respeita às estratégias de deteção/monitorização da cardiotoxicidade em indivíduos com cancro.

© 2012 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L. Todos os direitos reservados.

Introduction

Cancer treatment has made dramatic advances in recent years; the development of intensive antineoplastic therapies has substantially improved the prognosis of cancer patients.¹ However, despite its unquestionable benefits, the safety aspects of cancer therapy cannot be ignored, not least because these drugs' mechanisms of action can have harmful effects on the cardiovascular system.^{2,3}

Cancer is currently the second leading cause of death in Portugal after cardiovascular disease,⁴ and colorectal cancer is the leading cause of cancer-related mortality.⁵

For several decades, cancer therapy-induced cardiotoxic reactions were almost exclusively associated with the use of anthracyclines, but a new dimension appeared when it was recognized that drugs targeting the action of certain tyrosine kinase receptors or tumor (estrogen) receptors can have undesirable clinical effects on the cardiovascular system.^{3,6}

A large part of the literature on the cardiotoxicity of cancer therapy deals solely with cardiomyopathy, but this is only one of several forms of cardiac dysfunction.⁷ Others may result in ischemia or changes in blood pressure,⁸ while antineoplastic agents can lead to thickening of the pericardium or disrupt pericardial fluid balance, resulting in effusion.⁹ Such treatment can also increase the risk of arrhythmias in patients predisposed to ventricular ectopic beats.¹⁰

Protection of cardiac function is a constant challenge for the pharmaceutical industry, regulatory authorities and the physicians who have to deal with adverse reactions to various anticancer agents.³ Assessment of patients exposed to such drugs, analysis of the risks they pose to individuals and patient groups with cancer, prevention and mitigation of cardiac injury, monitoring of cardiac function during and after therapy, and treatment of chemotherapy-related cardiotoxicity, have all generated a vast quantity of knowledge and data that is collectively known as "cardio-oncology".^{7,11}

In this article we review the various responses to cardiotoxic cancer treatments, and their relationship with the main antineoplastic drugs used in clinical practice. In addition, we analyze the latest guidelines on detection and monitoring of cardiotoxicity in patients with cancer.

Definition of cardiotoxicity

A standard definition of cardiotoxicity is essential for both clinicians and researchers.³ One of the most precise definitions was proposed by the Cardiac Review and Evaluation Committee, as part of its oversight of clinical trials of the monoclonal antibody *trastuzumab* (Table 1).¹² The criteria do not include subclinical cardiovascular lesions which can occur as an initial response to some chemotherapeutic agents.¹³

Antineoplastic drugs and cardiomyopathy

The most common form of cardiotoxicity in cancer treatment is anthracycline-related cardiomyopathy.⁷ Initial evidence indicated that left ventricular (LV) systolic dysfunction was closely related to cumulative doses of

Table 1 Criteria to confirm or revise a preliminary diagnosis of cardiac dysfunction.

- (1) Cardiomyopathy characterized by a decrease in LVEF that was either global or more severe in the septum
- (2) Symptoms of CHF
- (3) Associated signs of CHF, including S3 gallop, tachycardia, or both
- (4) Decline in LVEF of at least 5% to less than 55% with signs or symptoms of CHF, or a decline in LVEF of at least 10% to below 55% without signs or symptoms

Adapted from Seidman et al.¹²

CHF: congestive heart failure; LVEF: left ventricular ejection fraction.

Table 2 Proposed classification of chemotherapy-related cardiomyopathy.

Type of drug	Prototype	Cumulative dose relationship	Reversibility
Type I	Doxorubicin Cyclophosphamide	Yes	No
Type II	Trastuzumab Sunitinib Sorafenib	No	Yes, in most cases

anthracyclines. According to Lefrak et al., repeated administration can result in permanent cellular and interstitial damage, frequently associated with refractory heart failure (HF),¹⁴ but new therapeutic agents such as trastuzumab, while they can also cause cardiomyopathy, induce transient and reversible myocyte dysfunction which is unrelated to the dose used, resulting in better prognosis.^{12,15}

Antineoplastic drugs are classified as type I agents, which cause irreversible damage, or type II, which do not (Table 2).¹⁵ Type II agents can be used for years before signs of cardiac injury appear and may be reintroduced after cardiac recovery with an acceptable level of risk.¹⁶ However, some clinical trials have cast doubt on whether the cardiotoxic effects of these drugs are in fact reversible, and combined anticancer therapy with class I and II agents is associated with a higher than expected incidence of cardiac dysfunction.¹⁷

Type I agents: anthracyclines

Anthracyclines, including doxorubicin (DOX), epirubicin (EPI) and daunorubicin (DNR), are still among the most frequently used antineoplastic agents in the treatment of a wide variety of solid tumors and blood cancers.³ Unfortunately, concerns among the medical community about their cardiotoxicity limit their use. Despite over 40 years of research, the mechanisms responsible for the cardiotoxicity of cumulative doses of anthracyclines have not been fully clarified.^{3,7}

Short- and long-term cardiotoxic effects

Cardiotoxicity can be acute or chronic, and can appear years after the end of treatment. Acute anthracycline-induced cardiotoxicity is rare, transient and dose-independent. It is characterized by sudden ventricular repolarization alterations, changes in QT interval, ventricular and supraventricular arrhythmias, acute coronary syndromes, pericarditis and myocarditis. These effects are usually observed from the beginning of treatment and up to 14 days after it ends.

Chronic toxicity is dose-dependent. It can be divided into two forms, according to the time of symptom onset. The first type occurs at the beginning of treatment and continues for a year after the end of chemotherapy, while the second type occurs later, more than a year after treatment. The most characteristic manifestation of chronic cardiotoxicity is ventricular systolic or diastolic dysfunction, which can lead to severe cardiomyopathy and even death.^{3,13}

Risk factors

The progression and degree of cardiotoxicity arising from the use of these drugs varies between individuals due to

the influence of various risk factors (Table 3) and genetic predisposition.³

The total cumulative dose is the main risk factor for anthracycline-related congestive HF.¹⁸ However, there is no completely safe dose, and so the cardiotoxicity of any given dosage must always be weighed against antineoplastic efficacy.¹⁹ Treatment duration may also influence the risk of cardiotoxicity during or after therapy; prolonged administration has been known to reduce the severity of cardiac injury,²⁰ while young patients appear to be more vulnerable to the cardiotoxic effects of these drugs.²¹

All risk factors are closely linked to early and late cardiotoxicity but not with acute forms.³

Pathophysiological mechanisms

Various mechanisms have been put forward to explain the pathophysiology of anthracycline-related cardiotoxicity, although it is still unclear why these drugs preferentially affect cardiomyocytes. The main hypotheses involve lipid peroxidation and oxidative stress in cardiomyocytes.²² The mechanism of action of anthracyclines suppresses the synthesis of DNA, RNA and proteins,²³ as well as of important transcription factors that regulate cardiospecific genes.^{24,25} Reduced protein expression, together with degradation of myofilaments, results in disruption of sarcomeric pro-

Table 3 Risk factors associated with anthracycline-induced cardiotoxicity.

Risk factor	Increased risk
Age	Younger
Gender	Female
Method of administration	Rapid intravenous injection
Cumulative dose	Exceeding: Daunorubicin 550–800 mg/m ² Doxorubicin 400–550 mg/m ² Epirubicin 900–1000 mg/m ² Idarubicin 150–225 mg/m ² Amsacrine 580 mg/m ² Mitoxantrone >100–140 mg/m ²
Mediastinal radiation	Early mediastinal radiation, or concomitant doxorubicin exceeding a cumulative dose of 450 mg/m ²
Previous cardiovascular disease	Hypertension, coronary disease
Electrolyte disturbances	Hypocalcemia, hypomagnesemia

teins such as titin in cardiac cells, leading to cardiac sarcopenia.²⁶ At the same time, destruction of myofibrils may be worsened by combined therapies such as anthracyclines with trastuzumab,¹⁶ which can also affect bioenergetics²⁷ and damage DNA.²⁸ Anthracyclines also disrupt the dynamic regulation of cardiac function, altering adrenergic and adenylyl cyclase activity²⁹ and calcium homeostasis.^{27,30}

Clinical and experimental evidence suggests that another possible mechanism for cardiotoxicity is cardiac cell death by apoptosis or necrosis after each exposure to anthracyclines. Given the limited regenerative capacity of the heart, the number of cardiomyocytes progressively falls, leading to ventricular remodeling.²² De Angelis et al. have demonstrated that DOX-induced cardiomyopathy can also be mediated by loss of cardiac stem cells and reversed by restoration of progenitor cell function.³¹

Strategies to limit cardiotoxicity

Although there is no generally accepted way to limit or prevent anthracycline cardiotoxicity, various strategies have been adopted, most notably the synthesis of analogues of the natural compounds, the development of tumor-specific formulations, and the use of cardioprotective agents.³²

Synthetic analogues of natural compounds. Changes in the structure of anthracyclines have produced compounds with low levels of cardiotoxicity, allowing the administration of higher doses.²² EPI³³ and idarubicin (IDA)³⁴ are viable alternatives to DOX and DNR, respectively. Other anthracyclines such as pirarubicin and aclarubicin, although registered in some countries, do not yet play a significant role in global terms.³⁵

Epirubicin. EPI is a semi-synthetic epimer of DOX with a similar oncological spectrum.³⁶ Although its mechanism of action is similar to that of DOX, some of its physical, chemical and pharmacokinetic properties are different,³² and it is significantly less cardiotoxic than DOX when administered in doses that result in the same level of myelosuppression.³⁶

Idarubicin. IDA is a structural analogue of DNR that intercalates into DNA, interacting with topoisomerase II and inhibiting nucleic acid synthesis.³² It is highly lipophilic and thus is easily absorbed into cells, and can be administered intravenously or orally. However, doubts have been expressed as to whether it is in fact any less cardiotoxic.^{35,37}

Tumor-specific formulations. New techniques have been developed to deliver anthracyclines in ways that reduce their absorption in cardiac tissue.³⁸ The current method for passive delivery of DOX and DNR to the target tumor is by incorporating them into liposomes,³⁹ which offers a good degree of cardioprotection by increasing the drug's molecular size through encapsulation and extending its elimination time. This enables the drug to remain in the organism for longer and with fewer adverse effects, and also keeps it away from organs that have normal capillary junctions, while easily penetrating areas with immature vascular systems, such as tumors.³⁸

By contrast, anthracycline prodrugs, unlike liposomal compounds, can reach the tumor by an active pathway. Various prodrugs have been developed by conjugating anti-

cancer agents with peptides, carbohydrates, antibodies, serum proteins and synthetic polymers.³⁵ These conjugates cannot penetrate normal cells and are activated specifically by cancer cells.^{35,40}

Cardioprotective agents. It is a priority to develop pharmacological therapies that protect the cardiovascular system without interfering with the antineoplastic effects of anthracyclines.^{32,41} Given the importance of reactive oxygen species (ROS) and oxidative stress in anthracycline-induced cardiotoxicity, research has focused on drugs and natural compounds that improve the antioxidant defenses of cardiomyocytes.⁴¹ Various types of drug, including antioxidants, iron-chelating agents and lipid-lowering drugs, have been tested in animal models and in humans,^{41–43} but the cardioprotective effect of some is highly questionable.^{42,43} Dexrazoxane (Cardioxane®) is the only drug approved for clinical use to prevent anthracycline-induced cardiotoxicity,⁴⁴ but controversy surrounds its use due to possible compromise of antineoplastic efficacy and increase in secondary tumors, and it has been restricted to adult patients by the US Food and Drug Administration.⁴⁵

Type II agents: trastuzumab

Monoclonal antibodies are among the best-known examples of targeted cancer therapy and are widely used. The *HER2* gene is overexpressed in 15–25% of breast cancers, resulting in overproduction of human epidermal growth factor receptor 2 (HER2). Trastuzumab binds to the extracellular domain of HER2, thereby inhibiting its signal transduction.⁷ Chemotherapeutic regimens that do not include anthracyclines result in lower rates of cardiac dysfunction than combined trastuzumab and anthracyclines, but trastuzumab associated with vinorelbine, gemcitabine or liposomal DOX do not present significant risk of cardiotoxicity.⁴⁶

Risk factors

One of the main risk factors for cardiotoxicity associated with trastuzumab is the use of high cumulative doses of anthracyclines (>300 mg/m²).⁴⁷ Other important risk factors include LV dysfunction, irrespective of anthracycline use, pre-existing systemic hypertension, body mass index >25 and advanced age. However, chest radiotherapy concomitantly with trastuzumab is clinically viable.⁴⁸

Recent evidence shows that elderly cancer patients (aged over 70) with a history of heart disease and/or diabetes present a higher incidence of trastuzumab-related cardiotoxic effects in breast cancer treatment. According to Serrano et al., this population should be closely and continuously monitored.⁴⁹

Pathophysiological mechanisms

The precise pathophysiological mechanisms by which trastuzumab acts within cells are not known, but they are thought to be closely linked to inhibition of HER2 cardiac signaling. Studies have demonstrated the important role of HER2 in cardiomyocyte survival and development^{50,51}; genetically modified mice with reduced HER2 levels develop dilated cardiomyopathy, reduced adaptation to pressure overload and greater sensitivity to anthracycline




Figure 1 In response to oxidative stress, neuregulin activates compensatory mechanisms via HER2 receptors (A); in the presence of trastuzumab, HER2/HER2 and HER2/HER4 dimers are blocked and the compensatory mechanisms are inactivated, leading to apoptosis and heart failure (B).

Adapted from Di Cosimo et al.⁵⁷.

toxicity,^{52,53} while at the cellular level overexpression of HER2 and/or neuregulin (NRG)-mediated activation of the HER2/HER4 signaling pathway confers greater protection against oxidative stress and prevents apoptosis.⁵⁴ High serum levels of HER2 have been detected in individuals with chronic HF,⁵⁵ and clinical trials have shown that administration of recombinant human NRG-1 improves cardiac function in chronic HF and is well tolerated.⁵⁶ Thus, while cardiac stress leads to increased HER2 expression and HER2/HER4 activation by NRG, inhibition of HER2 by trastuzumab induces ventricular dysfunction (Figure 1).⁵⁷

However, trastuzumab's pathophysiological mechanism is probably more complex and does not only involve HER2 inhibition. Studies have revealed low toxicity after the use of lapatinib, a tyrosine kinase inhibitor with dual action against HER2 and epidermal growth factor (EGF).⁵⁸ There may be various reasons for the differences in toxicity between these two drugs. Studies analyzing the effect on cardiomyocytes of cytotoxic immune reactions triggered by the IgG1 domain of trastuzumab show that antibody-dependent cell-mediated cytotoxicity in tumor cells is closely linked to cardiotoxicity.⁵⁹ Another suggested mechanism involves a single intracellular response after activation of HER2 in cardiomyocytes. After binding to HER2, trastuzumab modulates mitochondrial integrity via the BCL-X family of

proteins, depleting ATP and leading to contractile dysfunction. Curiously, some studies indicate that lapatinib has the opposite effect, reducing trastuzumab's cytotoxicity when the two drugs are administered together.^{60,61} This is due to their different effect on adenosine monophosphate-activated protein kinase (AMPK): while this is reduced by trastuzumab, reducing intracellular ATP, it is enhanced by lapatinib, leading to increased ATP production by oxidative pathways.⁶¹

Cardiotoxicity of concomitant trastuzumab and anthracyclines

The mechanisms of cardiotoxicity associated with concomitant use of trastuzumab and anthracyclines are of particular importance in view of the frequency with which combined therapy is used to treat breast cancer.⁶² Such therapy leads to increased ROS levels and reductions in antioxidant compounds, promoting oxidative stress that results in cardiac dysfunction and overexpression of angiotensin II (Ang II), high levels of which inhibit the action of NRG, preventing it from binding to HER receptors and thereby blocking antiapoptotic signaling pathways. Inhibition of these pathways can also increase ROS production, while Ang II also affects the activation and upregulation of NADPH oxidase^{63,64} by interacting with the G protein-coupled AT1 receptor, which activates NADPH oxidase




Figure 2 Interaction of the cardiotoxic mechanisms of anthracyclines with those of trastuzumab.

via protein kinase C.⁶³ NADPH oxidase in turn produces superoxide anion radicals, which are potent ROS. Finally, AT1 receptor signaling is linked to the activation of apoptosis signaling kinase 1 (ASK1), a member of the MAPK family, and thus leads to cell death and cardiac dysfunction.⁶⁵

To summarize, trastuzumab directly inhibits anti-apoptotic signaling pathways and causes overexpression of Ang II, which stimulates ROS production and inhibits the action of NRG (Figure 2).⁶⁶

Strategies to limit cardiotoxicity

Various strategies have been developed to reduce the cardiotoxicity of trastuzumab without significantly compromising its therapeutic efficacy, including optimization of chemotherapeutic combinations, shortening of treatment duration and careful monitoring of patients.⁵⁷

Trastuzumab without anthracyclines. The Breast Cancer International Research Group 006 trial was the first to test an adjuvant chemotherapeutic regimen with trastuzumab and without anthracyclines to treat breast cancer, which was shown to have equivalent antineoplastic efficacy with a lower incidence of cardiotoxic events than combined therapy with trastuzumab and anthracyclines.⁶⁷ Although other trials have confirmed the efficacy of this approach,⁶⁸ there are conflicting opinions regarding the role of anthracyclines in combined cancer treatments.⁶⁹

Trastuzumab-toxin conjugates. Monoclonal antibodies that are tumor-specific but insufficiently cytotoxic in

themselves can be chemically bound to cytotoxic agents to direct them to specific antigens on target tumors, which confers more control over apoptosis in tumor cells and greater selectivity in their action.⁷⁰ Phillips et al. demonstrated that trastuzumab conjugated with DM1, derived from the fungal toxin maytansine, is associated with low cardiotoxicity,⁷¹ and clinical trials have confirmed the efficacy and tolerability of the trastuzumab-DM1 conjugate to treat breast cancer.⁷²

Short-term treatment regimens. There is considerable interest in short-term treatment regimens due to their greater safety and better cost-benefit ratio.³ The Finland Herceptin (FinHER) trial compared adjuvant docetaxel and vinorelbine with or without trastuzumab for early breast cancer. Trastuzumab was administered before other cardiotoxic drugs and in combination with docetaxel and vinorelbine for only nine weeks, in order to test the hypothesis that this would reduce cardiotoxicity while maintaining antineoplastic efficacy. There was a strong association between low cardiotoxicity and short trastuzumab treatment regimens.⁷³

Individualized anthracycline therapy. Topoisomerase II- α (TOP2A) is a target for anthracyclines, and is considered a possible predictor of response to these agents. The *TOP2A* gene, which is located close to the *HER2* gene, is more often overexpressed in HER2-positive tumors (34–90%) than in other cancers (5–10%). Several reports and retrospective clinical analyses have found that treatment for HER2-positive breast cancer that included anthracyclines has greater efficacy, suggesting that anthracycline use should be

reduced in patients with HER2-negative tumors.^{74–76} However, clinical trials have drawn different conclusions,⁷⁷ and the use of adjuvant anthracyclines to treat patients with overexpression of both *HER2* and *TOP2A* remains the subject of debate.³

Other cardiotoxic effects

Myocardial ischemia

Individuals with cancer survive longer than they used to, which means that they are more exposed to the risk of atherosclerosis.⁷⁸ Certain antineoplastic drugs, particularly capecitabine, 5-fluorouracil (5-FU) and bevacizumab, are associated with coronary disease in cancer patients, while anti-microtubule agents (paclitaxel and docetaxel), tyrosine kinase inhibitors (sorafenib and sunitinib) and the Vinca alkaloids vincristine and vinorelbine have been linked to ischemic events.^{2,79}

The ischemic event most often associated with 5-FU or its fluoropyrimidine prodrug capecitabine is coronary vasospasm; many affected individuals have previous coronary disease, which may increase 5-FU's ischemic effect. Once the ischemic event is under control, treatment should resume, taking care to avoid recurrence.⁸⁰

Bevacizumab is a monoclonal antibody targeted at vascular endothelial growth factor (VEGF) that has demonstrated anti-tumor activity when combined with chemotherapy. This agent has occasionally been associated with arterial thromboembolic events, including myocardial infarction in 0.6–1.5% of patients.^{7,81} The mechanisms behind its cardiotoxicity are unclear.⁸²

Arrhythmias

The overall incidence of arrhythmias in cancer patients is unknown and varies with different treatments.⁸³ Risk factors include advanced age, radiotherapy of the heart, the presence of amyloid infiltration, and any underlying conduction system disturbance.² At the same time, cancer itself creates an arrhythmogenic environment independently of other risk factors.⁸³ Atrial fibrillation is the most prevalent arrhythmia in cancer patients, and according to Onaitis et al. is responsible for significant morbidity following cancer surgery, with an incidence of up to 12.6%.⁸⁴

It is difficult to establish a causal relationship between arrhythmic events and use of a particular drug. The chemotherapeutic agents known to cause arrhythmias are anthracyclines (DOX and EPI), anti-microtubule agents (paclitaxel and docetaxel), antimetabolites (capecitabine, 5-FU and gemcitabine), alkylating agents (cisplatin and cyclophosphamide), tyrosine kinase inhibitors (trastuzumab and cetuximab), arsenic trioxide, thalidomide and interleukin 2.⁸³

Systemic hypertension

Some antiangiogenic cancer drugs, including bevacizumab, sunitinib, sorafenib, vatalanib, pazopanib, motesanib, axitinib and aflibercept, induce or exacerbate systemic hypertension.^{85,86} Before the introduction of these drugs, the prevalence of hypertension in cancer patients was similar to the adult population in general, but the improved survival of these patients and wider use of chemotherapeu-




Figure 3 Radiotherapy-induced cardiotoxicity.

tic agents that affect systemic blood pressure mean that it is now diagnosed more frequently.^{85,86}

Antiangiogenic cancer drugs reduce the activity of the tyrosine kinase of VEGF receptors, which produce nitric oxide, increasing capillary permeability and endothelial cell proliferation.^{85,86} Pre-existing hypertension is an important risk factor for severe hypertensive sequelae in cancer patients, and aggressive antihypertensive medication before and during treatment with anti-angiogenic drugs is essential.²

Thromboembolism

Venous thromboembolism is a leading cause of death in cancer patients and is associated with the use of antiangiogenic drugs, thalidomide, lenalidomide, bevacizumab and hormone therapy such as tamoxifen.⁸⁷

The antineoplastic agent most often linked to thromboembolic events (5% incidence in monotherapy⁸⁸) is thalidomide.² Lenalidomide, a thalidomide analogue, is generally less toxic, but the risk of thromboembolism is still high.⁸⁹ The thrombogenic mechanism of these drugs involves direct action on endothelial cells and increased platelet aggregation.²

Tamoxifen, an estrogen receptor antagonist, is associated with increased thromboembolic complications,⁹⁰ while aromatase inhibitors such as anastrozole and letrozole, which block conversion of androgens to estrogen in postmenopausal women, have been linked to harmful cardiac effects (Table 4).⁹¹

Cardiotoxicity associated with radiotherapy

An estimated 50% of cancer patients receive radiotherapy, which, together with the development of new chemotherapeutic agents, has dramatically improved the prognosis of various types of cancer. However, late cardiovascular effects are frequently found following radiotherapy.⁹² Most clinical data on radiation-induced heart disease come from studies of individuals with breast cancer or Hodgkin's disease who developed symptomatic disease during or after treatment.⁹³ Pericardial disease is frequently associated with radiotherapy, but other disorders can appear months or years after treatment, including myocardial fibrosis and cardiomyopathy, accelerated coronary disease, conduction disturbances and valve dysfunction (Figure 3). The extent of cardiotoxicity depends mainly on radiation dose, the area of the heart exposed, and the particular technique applied. Other risk factors such as the patient's age at the time of exposure are

Table 4 Cardiotoxicity of the main classes of cancer drugs used in clinical practice.

Class	Examples	Cancers treated	Cardiotoxicity	Mechanism of action
Anthracyclines	Doxorubicin, epirubicin, daunorubicin, idarubicin, mitoxantrone	Acute leukemias, Hodgkin's and non-Hodgkin's lymphomas, breast cancer	<i>Acute</i> : HF, arrhythmias, QT interval changes, ventricular repolarization abnormalities <i>Chronic (dose-dependent)</i> : LV dysfunction (non-reversible)	Damage to cardiomyocytes: - Oxidative stress (ROS production) - Apoptosis ROS production
Alkylating agents	Cyclophosphamide	Bladder, endometrial, breast, ovarian, lung and blood cancers	Acute HF (usually reversible), pericardial effusion, arrhythmias Myocardial ischemia	–
Antimetabolites	Cisplatin 5-Fluorouracil Capecitabine	Solid tumors, including lung, colon and breast	Myocardial ischemia, MI, arrhythmias	Coronary spasm, cardiomyocyte toxicity
Anti-microtubule agents	Paclitaxel Docetaxel	Breast and ovarian cancer, Kaposi's sarcoma, non-small-cell lung cancer Breast cancer, non-small-cell lung cancer, head and neck cancers, prostate, bladder and ovarian cancer, gastric adenocarcinoma	Bradycardia, syncope, LV dysfunction, ventricular arrhythmias, myocardial ischemia	Damage to cardiomyocytes
Vinca alkaloids	Vincristine, vinblastine and vinorelbine	Leukemias and lymphomas	Myocardial ischemia	–
Tyrosine kinase inhibiting antibodies	Trastuzumab	Breast cancer	LV dysfunction (reversible)	HER2 receptor inhibition
	Bevacizumab	Metastatic colorectal cancer, lung cancer	Systemic hypertension, venous thrombosis, LV dysfunction	VEGF inhibition
	Rituximab	Lymphomas, leukemias, transplant rejection, some autoimmune disorders	Orthostatic hypotension	Associated with allergies and angioedema
	Alemtuzumab	Chronic lymphocytic leukemia, cutaneous T-cell lymphoma, T-cell lymphoma	Hypotension, myocardial ischemia, LV dysfunction	–

Table 4 (Continued)

Class	Examples	Cancers treated	Cardiotoxicity	Mechanism of action
Small-molecule tyrosine kinase inhibitors	Imatinib	Chronic myeloid leukemia, lymphoblastic leukemia, gastrointestinal stromal tumors	LV dysfunction	Inhibition of mitochondrial protection pathways
	Sunitinib	Renal cell carcinoma, imatinib-resistant gastrointestinal stromal tumors	LV dysfunction, HF, myocardial ischemia, hypertension, ECG alterations	Mitochondrial damage
	Sorafenib	Hepatocellular carcinoma, renal cell carcinoma	LV dysfunction	-
	Erlotinib	Lung and pancreatic cancer	Myocardial ischemia, MI	-
	Lapatinib	Breast cancer	LV dysfunction, HF	-
	Dasatinib	Chronic myeloid leukemia after imatinib treatment, acute lymphoblastic leukemia	LV dysfunction, HF	-
Unclassified	Gemcitabine	Non-small-cell lung cancer, pancreatic, breast and bladder cancer	Pericardial effusion	-
	Retinoic acid	Acute promyelocytic leukemia	Pericardial effusion, LV dysfunction	Retinoic acid syndrome
	Arsenic trioxide	Relapsing acute promyelocytic leukemia	Prolonged QT interval, torsades de pointes	Interaction with ion channels
	Tamoxifen	Breast cancer	Deep vein thrombosis, pulmonary embolism, stroke	-
	Thalidomide and lenalidomide	Multiple myeloma	Edema and sinus bradycardia, deep vein thrombosis	-
	Interleukin 2	Melanoma, metastatic renal cell carcinoma	Hypotension, arrhythmias, myocardial ischemia, cardiomyopathy, myocarditis	Septic shock

ECG: electrocardiographic; HER2: human epidermal growth factor receptor 2; HF: heart failure; LV: left ventricular; MI: myocardial infarction; ROS: reactive oxygen species.

Table 5 Advantages and disadvantages of the principal techniques used for monitoring cardiotoxicity in clinical practice.

Technique	Advantages	Disadvantages
<i>No longer used</i>		
Endomyocardial biopsy	Traditionally, though mistakenly, accepted as the gold standard Histological evidence of cardiac injury	Invasive Requires specialists to perform and to interpret the results Small samples of the myocardium obtained No functional information
<i>Current standard methods</i>		
Echocardiography	Non-invasive and low cost Morphological and functional assessment: systolic (LVEF, LV fractional shortening, systolic wall thickness) and diastolic parameters (E/A ratio, isovolumic relaxation time, pulmonary venous flow pattern) Information on valve structure and pericardium	Operator-dependent (intra- and inter-observer variability) LVEF assessment dependent on image quality and subject to variability Doubtful predictive value for early detection of subclinical damage
Radionuclide angiography	Well validated for determining LVEF Low intra- and inter-observer variability High reproducibility	Underestimates ventricular volumes Overestimates LVEF in smaller ventricles (children and women) Radiation exposure Low temporal and spatial resolution No information on valve function Little information on diastolic function Limited predictive value for early detection of subclinical damage
Electrocardiography	Non-invasive and low cost for arrhythmia screening Prolonged QT interval is recognized as a marker of cardiotoxicity	No information on LVEF QT values subject to problems with measurement, analysis and interpretation, and to intra- and inter-observer variability
<i>Promising techniques</i>		
Tissue Doppler	Detects isolated diastolic dysfunction Early detection of subclinical damage (combined with markers of inflammation/oxidative stress) Excellent temporal resolution Functional assessment: filling pressures (E/A ratio), systolic and diastolic ventricular wall velocities, strain and strain rate	Limited experience Time-consuming analysis
Stress echocardiography	Assessment of myocardial contractile reserve	Limited and controversial data on early detection of cardiotoxicity in cancer patients Semi-invasive
Magnetic resonance imaging	High reproducibility Functional and myocardial perfusion assessment: identification of post-MI scarring and viable myocardium Tissue characterization Useful in patients with poor echocardiographic window	Low temporal resolution High cost, especially when repeat exams are required Limited availability Only preliminary evidence on predictive value
Computed tomography	Good image quality (similar to magnetic resonance)	High radiation dose Limited availability Low temporal resolution

Table 5 (Continued)

Technique	Advantages	Disadvantages
Scintigraphy	Non-invasive Structural and functional assessment	Limited data Not in routine clinical use Radiation exposure
Biomarkers	Non-invasive Low inter-observer variability Assessment of cardiovascular function and of potential cardiac injury cTnT, BNP and glycogen phosphorylase BB are promising markers for early detection of myocardial damage with high sensitivity and specificity	Undetermined predictive value Not in routine clinical use
Endothelial damage	Cytokines, adhesion molecules and carotid artery intima-media thickness are potential alternative parameters to assess cardiovascular toxicity	Unknown predictive value
Genetic analysis	Minimally invasive Assessment of individual susceptibility	Unknown predictive value

Adapted from Raschi et al.³

BNP: brain natriuretic peptide; cTnT: cardiac troponin T; LV: left ventricular; LVEF: left ventricular ejection fraction; MI: myocardial infarction.

also important, with younger patients (aged under 20) being more susceptible to cardiac injury.⁹⁴

Testing and monitoring

Preclinical testing

It is generally accepted that before any anti-cancer compound is approved for commercial use, data from preclinical trials should guide cardiac monitoring during subsequent human trials.³ However, the precise molecular mechanisms behind the cardiotoxicity of some drugs are unknown, which makes prediction and early detection of such effects difficult at the pre-commercialization stage. Primary cardiac cell cultures are often used as models in toxicological testing, but embryonic stem cell-derived cardiomyocytes are also promising models that could increase available resources and improve the predictive ability of non-clinical tests.⁹⁵ Although a variety of animal models have been developed, they can only help to clarify the molecular mechanisms behind drug-induced cardiac dysfunction and cannot predict clinical outcomes.⁹⁶

Monitoring and early detection

The need to monitor patients treated with anthracyclines, even after the end of therapy, depends on specific factors such as the patient's age, radiation dose, and cumulative anthracycline dose.⁹⁷ Individual susceptibility, for example

genetic background, should also be assessed to identify vulnerable patients and to personalize treatment. Identification of high-risk subgroups and their incorporation into monitoring systems is strongly recommended.^{3,98}

Little is known of the long-term cardiac effects of drugs such as trastuzumab and the extent to which their cardiotoxic effects are reversible. This is mainly because medium-term (2–3 years in the case of trastuzumab) follow-up data do not indicate whether heart failure treatment results in permanent recovery or reduces the risk of late cardiac dysfunction. There has also been no systematic investigation of risk factors associated with cardiotoxicity in these compounds. Careful assessment of cardiac function is thus recommended in all eligible patients, especially those with reduced myocardial reserve.³

Left ventricular ejection fraction (LVEF) assessed by radionuclide angiography or echocardiography is the index most often used to monitor cardiac function during cancer treatment,⁹⁹ but it can underestimate cardiac damage due to the adaptive capacity of the myocardium, which can keep LVEF within normal limits even in the presence of myocardial dysfunction.¹⁰⁰ Other methods for early detection of cardiotoxicity have therefore been explored, including analysis of individual susceptibility, detection of temporary events such as release of natriuretic peptides, and identification of subclinical changes, such as variations in diastolic parameters (Table 5).⁹⁹

Although there are guidelines on monitoring for cardiotoxic effects, it is not known how long monitoring should continue after treatment ends.⁹⁹ Cardiovascular surveillance is thus essential in cancer patients in order to detect

the cardiotoxic effects of antineoplastic therapy as early as possible.

Conclusion

The extensive use of chemotherapy and radiotherapy in clinical practice has led to considerable controversy due to their potential adverse cardiovascular effects in surviving cancer patients, including cardiomyopathy, ischemia, arrhythmias, hypertension, pericardial disease and thromboembolism. There is no consensus on standardizing the monitoring of cardiac function in these patients, and no reliable models able to predict the risk of cardiotoxicity.

With regard to cancer drugs, specialists in the area recognize the need to understand the mechanisms responsible for cardiotoxicity. Careful management and assessment of cardiac risk is essential in these patients, and the long-term effects of different treatments require further study. To this end, it is increasingly important to establish dynamic partnerships between oncologists and cardiologists in order to reduce mortality and improve patients' quality of life, while maintaining the efficacy of the treatment.

To summarize, cardiotoxicity induced by cancer treatment should be considered a multidisciplinary problem, the approach to which should include basic science, oncology and cardiovascular medicine.

Ethical disclosures

Protection of human and animal subjects. The authors declare that no experiments were performed on humans or animals for this study.

Confidentiality of data. The authors declare that no patient data appear in this article.

Right to privacy and informed consent. The authors declare that no patient data appear in this article.

Conflicts of interest

The authors have no conflicts of interest to declare.

Acknowledgements

This work was funded by the Portuguese Foundation for Science and Technology (project no. FCOMP-01-0124-FEDER-011051, FEDER, COMPETE, Ref. FCT-PTDC/SAU-FCF/100442/2008), the João Porto 2008 Study Grant, and by the University of Porto/Santander Totta (Projectos pluridisciplinares IJUP 2009 and 2010). Carmen Brás-Silva is a researcher for *Programa Ciência* 2008.

References

1. Minami M, Matsumoto S, Horiuchi H. Cardiovascular side-effects of modern cancer therapy. *Circ J*. 2010;74:1779–86.
2. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. *J Am Coll Cardiol*. 2009;53:2231–47.
3. Raschi E, Vasina V, Ursino MG, et al. Anticancer drugs and cardiotoxicity: insights and perspectives in the era of targeted therapy. *Pharmacol Ther*. 2010;125:196–218.
4. Araújo A, Barata F, Barroso S, et al. Cost of cancer care in Portugal. *Acta Med Port*. 2009;22:525–36.
5. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. *Eur J Cancer*. 2010;46:765–81.
6. Viale PH, Yamamoto DS. Cardiovascular toxicity associated with cancer treatment. *Clin J Oncol Nurs*. 2008;12:627–38.
7. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. *Nat Rev Cardiol*. 2010;7:564–75.
8. López Medrano F, Sánchez Muñoz A, Sánchez Sánchez V, et al. Cardiotoxicity of 5-fluorouracil: ischemia or myocardial toxicity? *Rev Clin Esp*. 2001;201:106–7.
9. Lestuzzi C. Neoplastic pericardial disease: old and current strategies for diagnosis and management. *World J Cardiol*. 2010;2:270–9.
10. Barbey JT, Soignet S. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. *Ann Intern Med*. 2001;135:842–3.
11. Eschenhagen T, Force T, Ewer MS, et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail*. 2011;13:1–10.
12. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. *J Clin Oncol*. 2002;20:1215–21.
13. Albini A, Pennesi G, Donatelli F, et al. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. *J Natl Cancer Inst*. 2010;102:14–25.
14. Lefrak EA, Pitha J, Rosenheim S, et al. A clinicopathologic analysis of adriamycin cardiotoxicity. *Cancer*. 1973;32:302–14.
15. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. *J Clin Oncol*. 2005;23:2900–2.
16. Ewer MS, Voelletich MT, Durand JB, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. *J Clin Oncol*. 2005;23:7820–6.
17. Telli ML, Hunt SA, Carlson RW, et al. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. *J Clin Oncol*. 2007;25:3525–33.
18. Ryberg M, Nielsen D, Skovsgaard T, et al. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. *J Clin Oncol*. 1998;16:3502–8.
19. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. *J Clin Oncol*. 2005;23:2629–36.
20. Hortobagyi GN, Frye D, Buzdar AU, et al. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. *Cancer*. 1989;63:37–45.

21. Kremer LC, van Dalen EC, Offringa M, et al. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. *J Clin Oncol.* 2001;19:191–6.
22. Sawyer DB, Peng X, Chen B, et al. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? *Prog Cardiovasc Dis.* 2010;53:105–13.
23. Olson RD, Mushlin PS. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. *FASEB J.* 1990;4:3076–86.
24. Ito H, Miller SC, Billingham ME, et al. Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. *Proc Natl Acad Sci U S A.* 1990;87:4275–9.
25. Jeyaseelan R, Poizat C, Wu HY, et al. Molecular mechanisms of doxorubicin-induced cardiomyopathy. Selective suppression of Riske iron-sulfur protein, ADP/ATP translocase, and phosphofructokinase genes is associated with ATP depletion in rat cardiomyocytes. *J Biol Chem.* 1997;272:5828–32.
26. Lim CC, Zuppinger C, Guo X, et al. Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes. *J Biol Chem.* 2004;279:8290–9.
27. Takahashi S, Denvir MA, Harder L, et al. Effects of in vitro and in vivo exposure to doxorubicin (adriamycin) on caffeine-induced Ca²⁺ release from sarcoplasmic reticulum and contractile protein function in 'chemically-skinned' rabbit ventricular trabeculae. *Jpn J Pharmacol.* 1998;76:405–13.
28. Lebrecht D, Kokkari A, Ketelsen UP, et al. Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin. *J Pathol.* 2005;207:436–44.
29. Fu M, Matoba M, Liang QM, et al. Properties of G-protein modulated receptor-adenylyl cyclase system in myocardium of spontaneously hypertensive rats treated with adriamycin. *Int J Cardiol.* 1994;44:9–18.
30. Dodd DA, Atkinson JB, Olson RD, et al. Doxorubicin cardiomyopathy is associated with a decrease in calcium release channel of the sarcoplasmic reticulum in a chronic rabbit model. *J Clin Invest.* 1993;91:1697–705.
31. De Angelis A, Piegari E, Cappetta D, et al. Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. *Circulation.* 2010;121:276–92.
32. Mordente A, Meucci E, Silvestrini A, et al. New developments in anthracycline-induced cardiotoxicity. *Curr Med Chem.* 2009;16:1656–72.
33. Ganzina F. 4'-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data. *Cancer Treat Rev.* 1983;10:1–22.
34. Ganzina F, Pacciarini MA, di Pietro N. Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies. *Invest New Drugs.* 1986;4:85–105.
35. Kratz F, Warnecke A, Schmid B, et al. Prodrugs of anthracyclines in cancer chemotherapy. *Curr Med Chem.* 2006;13:477–523.
36. van Dalen EC, Michiels EM, Caron HN, et al. Different anthracycline derivatives for reducing cardiotoxicity in cancer patients. *Cochrane Database Syst Rev.* 2010;CD005006.
37. Cortés-Funes H, Coronado C. Role of anthracyclines in the era of targeted therapy. *Cardiovasc Toxicol.* 2007;7:56–60.
38. Slingerland M, Guchelaar HJ, Gelderblom H. Liposomal drug formulations in cancer therapy: 15 years along the road. *Drug Discov Today.* 2012;17:160–6.
39. Abraham SA, Waterhouse DN, Mayer LD, et al. The liposomal formulation of doxorubicin. *Methods Enzymol.* 2005;391:71–97.
40. Sessa C, Valota O, Geroni C. Ongoing phase I and II studies of novel anthracyclines. *Cardiovasc Toxicol.* 2007;7:75–9.
41. Wouters KA, Kremer LC, Miller TL, et al. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. *Br J Haematol.* 2005;131:561–78.
42. Myers C, Bonow R, Palmeri S, et al. A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. *Semin Oncol.* 1983;10:53–5.
43. Ladas EJ, Jacobson JS, Kennedy DD, et al. Antioxidants and cancer therapy: a systematic review. *J Clin Oncol.* 2004;22:517–28.
44. Schuchter LM, Hensley ML, Meropol NJ, et al. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. *J Clin Oncol.* 2002;20:2895–903.
45. Swain SM. Adult multicenter trials using dexrazoxane to protect against cardiac toxicity. *Semin Oncol.* 1998;25:43–7.
46. Martin M, Esteva FJ, Alba E, et al. Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations. *Oncologist.* 2009;14:1–11.
47. Swain SM, Whaley FS, Gerber MC, et al. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. *J Clin Oncol.* 1997;15:1333–40.
48. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. *N Engl J Med.* 2005;353:1659–72.
49. Serrano C, Cortés J, de Mattos-Arruda L, et al. Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. *Ann Oncol.* 2011;23:897–902.
50. Lee KF, Simon H, Chen H, et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development. *Nature.* 1995;378:394–8.
51. Zhao YY, Sawyer DR, Baliga RR, et al. Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. *J Biol Chem.* 1998;273:10261–9.
52. Ozelik C, Erdmann B, Pilz B, et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. *Proc Natl Acad Sci U S A.* 2002;99:8880–5.
53. Crone SA, Zhao YY, Fan L, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. *Nat Med.* 2002;8:459–65.
54. Lemmens K, Doggen K, de Keulenaer GW. Role of neuregulin-1/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure. *Circulation.* 2007;116:954–60.
55. Perik PJ, de Vries EG, Gietema JA, et al. Serum HER2 levels are increased in patients with chronic heart failure. *Eur J Heart Fail.* 2007;9:173–7.
56. Jabbour A, Hayward CS, Keogh AM, et al. Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses. *Eur J Heart Fail.* 2011;13:83–92.
57. Di Cosimo S. Heart to heart with trastuzumab: a review on cardiac toxicity. *Target Oncol.* 2011;6:189–95.
58. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. *N Engl J Med.* 2006;355:2733–43.
59. Sliwkowski MX, Lofgren JA, Lewis GD, et al. Nonclinical studies addressing the mechanism of action of trastuzumab (herceptin). *Semin Oncol.* 1999;26:60–70.
60. Shell SA, Lyass L, Trusk PB, et al. Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells. *Cell Cycle.* 2008;7:1769–75.
61. Spector NL, Yarden Y, Smith B, et al. Activation of AMP-activated protein kinase by human EGF receptor 2/EGF

- receptor tyrosine kinase inhibitor protects cardiac cells. *Proc Natl Acad Sci U S A*. 2007;104:10607–12.
62. Albin A, Cesana E, Donatelli F, et al. Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors. *Future Cardiol*. 2011;7:693–704.
 63. Nakagami H, Takemoto M, Liao JK. NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy. *J Mol Cell Cardiol*. 2003;35:851–9.
 64. Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. *Circulation*. 2006;114:2474–81.
 65. Lemarié CA, Paradis P, Schiffrin EL. New insights on signaling cascades induced by cross-talk between angiotensin II and aldosterone. *J Mol Med (Berl)*. 2008;86:673–8.
 66. Zeglinski M, Ludke A, Jassal DS, et al. Trastuzumab-induced cardiac dysfunction: a 'dual-hit'. *Exp Clin Cardiol*. 2011;16:70–4.
 67. Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. *J Clin Oncol*. 2006;24:2786–92.
 68. Glück S, McKenna Jr EF, Royce M. Xena: capecitabine plus docetaxel, with or without trastuzumab, as preoperative therapy for early breast cancer. *Int J Med Sci*. 2008;5:341–6.
 69. Castrellon AB, Glück S. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary? *Clin Adv Hematol Oncol*. 2008;6:666–72.
 70. Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. *Acc Chem Res*. 2008;41:98–107.
 71. Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. *Cancer Res*. 2008;68:9280–9.
 72. Burris 3rd HA, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. *J Clin Oncol*. 2011;29:398–405.
 73. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. *N Engl J Med*. 2006;354:809–20.
 74. Muss HB, Thor AD, Berry DA, et al. C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. *N Engl J Med*. 1994;330:1260–6.
 75. Di Leo A, Gancberg D, Larsimont D, et al. HER-2 amplification and topoisomerase II α gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. *Clin Cancer Res*. 2002;8:1107–16.
 76. Villman K, Sjöström J, Heikkilä R, et al. TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer. *Acta Oncol*. 2006;45:590–6.
 77. Bartlett JM, Munro A, Cameron DA, et al. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. *J Clin Oncol*. 2008;26:5027–35.
 78. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons; endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. *Circulation*. 2007;116:e148–304.
 79. Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. *Circulation*. 2004;109:3122–31.
 80. Kosmas C, Kallistratos MS, Kopterides P, et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. *J Cancer Res Clin Oncol*. 2008;134:75–82.
 81. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. *J Natl Cancer Inst*. 2007;99:1232–9.
 82. Zambelli A, della Porta MG, Eleuteri E, et al. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues. *Breast*. 2011;20:176–83.
 83. Guglin M, Aljayeh M, Saiyad S, et al. Introducing a new entity: chemotherapy-induced arrhythmia. *Europace*. 2009;11:1579–86.
 84. Onaitis M, D'Amico T, Zhao Y, et al. Risk factors for atrial fibrillation after lung cancer surgery: analysis of the Society of Thoracic Surgeons general thoracic surgery database. *Ann Thorac Surg*. 2010;90:368–74.
 85. Izzedine H, Ederhy S, Goldwasser F, et al. Management of hypertension in angiogenesis inhibitor-treated patients. *Ann Oncol*. 2009;20:807–15.
 86. Scartozzi M, Galizia E, Chiorrini S, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. *Ann Oncol*. 2009;20:227–30.
 87. Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. *J Thromb Haemost*. 2007;5:632–4.
 88. Rodeghiero F, Elice F. Thalidomide and thrombosis. *Pathophysiol Haemost Thromb*. 2003;33:15–8.
 89. Hirsh J. Risk of thrombosis with lenalidomide and its prevention with aspirin. *Chest*. 2007;131:275–7.
 90. Deitcher SR, Gomes MP. The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review. *Cancer*. 2004;101:439–49.
 91. Ewer MS, Glück S. A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health. *Cancer*. 2009;115:1813–26.
 92. Yusuf SW, Sami S, Daher IN. Radiation-induced heart disease: a clinical update. *Cardiol Res Pract*. 2011;2011:317659.
 93. Veinot JP, Edwards WD. Pathology of radiation-induced heart disease: a surgical and autopsy study of 27 cases. *Hum Pathol*. 1996;27:766–73.
 94. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. *JAMA*. 1993;270:1949–55.
 95. Kettenhofen R, Bohlen H. Preclinical assessment of cardiac toxicity. *Drug Discov Today*. 2008;13:702–7.
 96. Barros TP, Alderton WK, Reynolds HM, et al. Zebrafish: an emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery. *Br J Pharmacol*. 2008;154:1400–13.
 97. Shankar SM, Marina N, Hudson MM, et al. Monitoring for cardiovascular disease in survivors of childhood can-

- cer: report from the Cardiovascular Disease Task Force of the Children's Oncology Group. *Pediatrics*. 2008;121:e387-96.
98. Trachtenberg BH, Landy DC, Franco VI, et al. Anthracycline-associated cardiotoxicity in survivors of childhood cancer. *Pediatr Cardiol*. 2011;32:342-53.
99. Altena R, Perik PJ, van Veldhuisen DJ, et al. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. *Lancet Oncol*. 2009;10:391-9.
100. Lester SJ, Tajik AJ, Nishimura RA, et al. Unlocking the mysteries of diastolic function: deciphering the Rosetta Stone 10 years later. *J Am Coll Cardiol*. 2008;51:679-89.